Fidelity Disruptive Medicine ETF(FMED.US)

Company Encyclopedia
View More
name
Fidelity Disruptive Medicine ETF
FMED.US
News
View More

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact | ALNY Stock News

Alnylam Pharmaceuticals has launched its "Alnylam 2030" strategy aimed at driving growth and patient impact. The company projects full-year 2025 net product revenues of $2.987 billion, an 81% increase from 2024, primarily from TTR revenues. For 2026, Alnylam anticipates combined net product revenues between $4.9 billion and $5.3 billion. The strategy focuses on achieving leadership in ATTR amyloidosis, sustainable innovation, and disciplined financial growth, with goals to deliver new transformative medicines and maintain a 25% revenue CAGR through 2030.

StockTitan·
US
ALNY
-0.28%
StockTitan·
US
ALNY
-0.28%

23:26 ET Veeva stellt eine Umweltüberwachungslösung zur Modernisierung der Qualitätskontrolle in der Fertigung vor

Veeva Systems (NYSE: VEEV) has announced a new Environmental Monitoring (EM) solution aimed at enhancing quality control (QC) in manufacturing. This cloud-based application integrates with Veeva LIMS, allowing labs and production sites to plan, collect, and analyze environmental samples to ensure compliance with GMP and internal sterility standards. The solution is part of Veeva Quality Cloud and is expected to be available in December 2026. Veeva aims to modernize quality and manufacturing processes by eliminating outdated technologies and streamlining batch release procedures.

prnewswire·
US
VEEV
-0.43%
prnewswire·
US
VEEV
-0.43%

If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today

Over the past 5 years, argenx (NASDAQ:ARGX) has outperformed the market with an average annual return of 24.32%, leading to a current market capitalization of $49.11 billion. An investment of $1000 in ARGX stock five years ago would now be worth $2,875.10, highlighting the significant impact of compounded returns on investment growth.

benzinga_article·
US
ARGX
-0.89%
benzinga_article·
US
ARGX
-0.89%

$100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth This Much Today

Intuitive Surgical (NASDAQ:ISRG) has delivered an average annual return of 20.44% over the past 20 years, outperforming the market by 11.68%. With a current market capitalization of $200.64 billion, a $100 investment in ISRG stock two decades ago would now be worth $4,041.87, highlighting the significant impact of compounded returns on investment growth.

benzinga_article·
US
ISRG
+0.20%
benzinga_article·
US
ISRG
+0.20%

If You Invested $100 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today

Boston Scientific (NYSE:BSX) has delivered an average annual return of 18.55% over the past 15 years, outperforming the market by 6.72%. With a current market capitalization of $141.10 billion, a $100 investment in BSX stock 15 years ago would now be worth $1,278.18, highlighting the significant impact of compounded returns on investment growth.

benzinga_article·
US
BSX
-0.75%
benzinga_article·
US
BSX
-0.75%
© 2026 Longbridge｜Disclaimer